eicosapentaenoic acid ethyl ester has been researched along with Fatty Liver in 3 studies
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary efficacy end point was NAFLD activity score ≤ 3, without worsening of fibrosis; or a decrease in NAFLD activity score by ≥ 2 with contribution from >1 parameter, without worsening of fibrosis, 1 year after the last dose of EPA-E or placebo was given." | 2.79 | No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. ( Abdelmalek, MF; Chojkier, M; Cummings, OW; Sanyal, AJ; Suzuki, A, 2014) |
| "Eicosapentaenoic acid (EPA) is a member of the family of n-3 polyunsaturated fatty acids (PUFAs) that are clinically used to treat hypertriglyceridemia." | 1.35 | Highly purified eicosapentaenoic acid prevents the progression of hepatic steatosis by repressing monounsaturated fatty acid synthesis in high-fat/high-sucrose diet-fed mice. ( Harada, T; Imada, K; Kajikawa, S; Kawashima, A; Mizuguchi, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sanyal, AJ | 1 |
| Abdelmalek, MF | 1 |
| Suzuki, A | 1 |
| Cummings, OW | 1 |
| Chojkier, M | 1 |
| Kajikawa, S | 1 |
| Harada, T | 1 |
| Kawashima, A | 1 |
| Imada, K | 1 |
| Mizuguchi, K | 1 |
| Kurihara, T | 1 |
| Tsuchiya, M | 1 |
| Akimoto, M | 1 |
| Hashimoto, H | 1 |
| Ishiguro, H | 1 |
| Niimi, A | 1 |
| Maeda, A | 1 |
| Shigemoto, M | 1 |
| Yamashita, K | 1 |
| Yokoyama, I | 1 |
| Kikuchi, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH[NCT01154985] | Phase 2 | 243 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Mean change from baseline at month 3 analyzed by Analysis of Covariance (ANCOVA) in the efficacy evaluable analysis set with treatment group as a factor and baseline ALT as a covariate. Principal comparisons were the response between;~EPA-E 2700 mg and Placebo groups~EPA-E 1800 mg and Placebo groups" (NCT01154985)
Timeframe: 3 month endpoint
| Intervention | U/L (Least Squares Mean) |
|---|---|
| Placebo | -19.3 |
| EPA-E 1800 mg/Day | -3.0 |
| EPA-E 2700 mg/Day | 2.8 |
"Mean change from baseline at month 6 analyzed by Analysis of Covariance (ANCOVA) in the efficacy analysis set with treatment group as a factor and baseline ALT as a covariate. Principal comparisons were the response between;~EPA-E 2700 mg and Placebo groups~EPA-E 1800 mg and Placebo groups" (NCT01154985)
Timeframe: 6 months
| Intervention | U/L (Mean) |
|---|---|
| Placebo | -19.1 |
| EPA-E 1800 mg/Day | -9.5 |
| EPA-E 2700 mg/Day | -3.0 |
"Patient is considered a responder if histological examination shows:~Composite NAS of <=3 AND no worsening in Fibrosis OR Improvement in NAS by >=2 across at least 2 of the NAS components AND no worsening in fibrosis~A priori threshold for statistical significance is p<0.05, 1-sided" (NCT01154985)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Placebo | 18 |
| EPA-E 1800 mg/Day | 18 |
| EPA-E 2700 mg/Day | 20 |
1 trial available for eicosapentaenoic acid ethyl ester and Fatty Liver
| Article | Year |
|---|---|
No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.
Topics: Biopsy; Disease Progression; Double-Blind Method; Eicosapentaenoic Acid; Fatty Liver; Female; Humans | 2014 |
2 other studies available for eicosapentaenoic acid ethyl ester and Fatty Liver
| Article | Year |
|---|---|
Highly purified eicosapentaenoic acid prevents the progression of hepatic steatosis by repressing monounsaturated fatty acid synthesis in high-fat/high-sucrose diet-fed mice.
Topics: Animals; Dietary Fats; Eicosapentaenoic Acid; Fatty Acids, Monounsaturated; Fatty Liver; Gene Expres | 2009 |
[Blood rheological study in rats with fatty liver--with special reference to effects of ethyl icosapentate].
Topics: Animals; Eicosapentaenoic Acid; Fatty Acids; Fatty Liver; Liver; Liver Circulation; Male; Platelet A | 1997 |